On January 20, the news of the digging shell network, The listed enterprise of the Beijing Stock Exchange, Jinhao Medical (872925), recently received 7 institutions such as Zhongtai Securities and Great Wall Fund for investigation. The company said that at present, some products have gradually used autonomous algorithms, and the company's products will gradually apply autonomous chips in the future.
On January 19th, Jinhao Medical received research from 7 institutions: Zhongtai Securities Co., Ltd., Shanghai Chuangda Asset Management Co., Ltd., Shanxi Securities Co., Ltd., Great Wall Fund Management Co., Ltd., Capstone Fund Management Co., Ltd., Shanghai Bank Fund Management Co., Ltd., and Shanghai Shangya Investment Management Co., Ltd.
In terms of the progress of the company's fundraising projects, Jinhao Medical said that the company's fundraising projects are still in the infrastructure stage and are expected to complete the construction of the main project by the third quarter of 2022. The company currently has a production capacity of about 1.5 million units per year, but due to the impact of site restrictions, the room for improvement is limited. New production capacity is gradually increased and released, with the opening of the U.S. OTC market and the development of the domestic market, the new market demand is conducive to the digestion of the company's production capacity.
For the advantages of the company's products in domestic similar products, the company said that it mainly includes the autonomous algorithms and chips of hearing aids, as well as a rich product line. At present, some products have gradually used autonomous algorithms, and in the future, with the delivery and use of autonomous chips, the company's products will gradually apply autonomous chips.
The application of artificial intelligence in the company's hearing aid products has also attracted attention. According to Jinhao Medical, the artificial intelligence in the company's hearing aid products is mainly reflected in the algorithm, such as adaptive switching in different scenarios.
Regarding the sales channels of the company's own brands and future development plans, Jinhao Medical said that the sales channels are mainly Amazon and domestic e-commerce platforms. With the intensification of the aging of the Chinese population, the company will focus on the layout of the domestic hearing aid market in the future, vigorously develop its own brands, and increase the proportion of its own brand sales.
According to the data of the Digging Shell Research Institute, Jinhao Medical is a medical device manufacturer, and its products are divided into hearing aids, atomizers, anti-decubitus cushions, etc., of which hearing aids are the company's main products. The company's hearing aids and other products are mainly sold overseas, customers include Germany's Sivanto, Japan's green oak, Germany's Borle and other well-known enterprises, but also with the supermarket giant Wal-Mart, Carrefour, the United States retail pharmacy giant CVS, India's retail chinese medicine giant APPOLO and other cooperative relations.
This article originated from the digging shell network
![Handsome guy with full eyes: Xu Jingtao, the words of the national team curler have always inspired me, and although it is very difficult at the moment, this experience may come to fruition in the future. I always[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)